VivoSeq
Infectious Disease

SARS Cov 2 Infection

1

Pipeline Programs↗

6

Active Trials↗

4

Companies Involved↗

SARS CoV 2 Infection is an early-stage landscape with 1 program across 4 companies. The most active players are Pfizer, Eli Lilly, Tonix Pharmaceuticals, Inc.. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3T

Tonix Pharmaceuticals, Inc.

0 programs

PreclinicalShionogi logo

Shionogi

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31

Ibuzatrelvir

Pfizer

Approved
No programs

Analysis

Trial Status

25

clinical trials

Completed12 · 48%
Unknown status5 · 20%
Recruiting3 · 12%
Not yet recruiting2 · 8%
Terminated1 · 4%
Withdrawn1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

25 trials

Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection
Recruiting·CConsorci Sanitari de Terrassa·N/A·NCT05504057·140,660 enrolled
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
Recruiting·UUniversity of Chicago·Phase 4·NCT06008860·280 enrolled
AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID-19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS
Recruiting·Pfizer logoPfizer·Phase 3·NCT06679140·2,330 enrolled
Cellular Senescence and Its Contribution to COVID-19 Long-Hauler Syndrome
Active, not recruiting·MMayo Clinic·N/A·NCT04903132·200 enrolled
Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients
Not yet recruiting·NNational Taiwan University Hospital·N/A·NCT06610643·40 enrolled
Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction
Not yet recruiting·HHuashan Hospital·N/A·NCT06597682·632 enrolled
A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection
Completed·CCelltrion·Phase 2/3·NCT04602000·1,642 enrolled
Host-pathogen Interactions During SARS-CoV-2 Infection
Completed·HHospices Civils de Lyon·N/A·NCT04376476·140 enrolled
Colostrum From MERS-CoV Seropositive Camels for SARS-CoV-2 Infection - a Placebo-controlled Randomized Trial.
Completed·HHadassah Medical Organization·Phase 1/2·NCT06857318·43 enrolled
Qualitative and Functional Investigation of Lipids in Patients With SARS-CoV2 Infection - In Search of Atherogenic Sequelae
Completed·—·N/A·NCT05476224·228 enrolled
VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
Completed·VVeru Inc.·Phase 3·NCT04842747·204 enrolled
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection
Completed·CCentre Leon Berard·Phase 2·NCT04333914·19 enrolled
Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection
Completed·TThe Ninth Hospital of Nanchang·Phase 4·NCT04291729·11 enrolled
A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of Individuals Infected With SARS-CoV-2
Completed·—·N/A·NCT05765279·281 enrolled
Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection
Completed·HHuoshenshan Hospital·Phase 4·NCT04345276·10 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)